Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infected patient~* Age 18 years or older~* Presence of pneumonia~* PaO2/FiO2 \< 300 mm Hg or SpO2 \< 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in \[94-98%\] or lung infiltrates \> 50%~* Medical insurance~Exclusion Criteria:~* Presence of do-not-resuscitate order~* Pregnancy~* Prisoners~* Known Naproxen allergy or intolerance~* Severe renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Naproxen (Type: EXPERIMENTAL): Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
- 2: Standard of care (Type: PLACEBO_COMPARATOR): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).